| 2026-06-01 |
Innovent Biologics (Suzhou) Co. Ltd. |
Results 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer innoventbio.com ↗
After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in IO-resistant squamous NSCLC and adenoNSCLC |
| 2026-06-01 |
Innovent Biologics (Suzhou) Co. Ltd. |
Results 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC innoventbio.com ↗
|
| 2026-05-22 |
Innovent Biologics (Suzhou) Co. Ltd. |
Results 2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable Safety innoventbio.com ↗
The preliminary results showed that IBI363 combined with PDC demonstrated encouraging efficacy signals in the first-line treatment of NSCLC with PD-L1 negative or low expression. |
| 2026-05-22 |
Innovent Biologics (Suzhou) Co. Ltd. |
Results 2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer innoventbio.com ↗
Updated data from this PoC study conducted in China, showed that after extended follow-up, IBI363 continued to demonstrate a manageable long-term safety profile in IO-resistant NSCLC. |
| 2026-05-11 |
Innovent Biologics (Suzhou) Co. Ltd. |
Regulatory Innovent Announces IBI363 (PD-1/IL-2α-bias Bispecific Fusion Protein) Received Third NMPA Breakthrough Therapy Designation for MSS/pMMR Metastatic Colorectal Cancer innoventbio.com ↗
|